AdAlta Ltd (1AD) is an Australian-based drug development company headquartered in Melbourne. The Company is using its proprietary technology platform to generate a promising new class of single domain antibody protein therapeutics, known as i-bodies, that have the potential to treat some of today’s most challenging medical conditions. The technology mimics the shape and stability of a antigen-binding domain, that was discovered initially in sharks and then developed as a human protein.
AdAlta Limited belongs to Health Care sector and under industry of Biotechnology. You can get more information about this company via their website: http://www.adalta.com.au.
This a small cap company with market cap of 45 millions.
Compared to Market and Sector
The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.
Company PE is less than both sector and market. while Company PB is greater than both sector and market. On the other hand, Company Earning is less than both sector and market.
Dividend Growth Chart
The following chart shows you how 1ad dividend grows in the recent years.